Overview
To evaluate the current medical practice and its influence on health-related quality of life, in patients who are treated with injectable bone antiresorptive drugs (biphosphonates or denosumab) for at least one year.
Description
This protocol will evaluate the pursuit of injectable bone antiresorptive treatments or their switch to oral biphosphonates, or treatment stop, in the contexte of medical practice.
The primary end-point is the health-related quality of life (QoL). Secondary endpoints are safety, overall survial, the impact of toxicities of the treatment on QoL, and the description of supportive care.
Eligibility
Inclusion Criteria:
- Patient with histologically proven tumor with bone metastasis, single or multiple (with or without metastasis extra-osseous)
- Patients treated with injectable bone antiresorptive therapy for 12 months or more
- Signed written informed consent
Exclusion Criteria:
- patient with any medical or psychiatric condition or disease which would make the patient inappropriate to complete quality of life questionaries
- patient under guardianship, curator or under the protection of justice, pregnant or breast-feeding women